- Follicular dendritic cells in B-cell small lymphocytic lymphoma2001 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PCYC-1130-CAPublication without faculty affiliation
- Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial2023 | Faculty of Medicine in Hradec Králové
- Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group2021 | Faculty of Medicine in Hradec Králové, Central Library of Charles University
- The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Immunohistochemical evidence of follicular dendritic cells in diagnostics of small B - cell lymphomas2003 | Faculty of Medicine in Pilsen
- Immunohistochemical evidence of follicular dendritic cells in diagnostics of small B - cell lymphomas2003 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Atypical picture of colon infiltration with lymphoma in a patient with chronic lymphocytic leukaemia2015 | Faculty of Medicine in Hradec Králové
- Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial2019 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial2022 | Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study2021 | Faculty of Medicine in Hradec Králové
- Other malignancies in the history of CLL: an international multicenter study coducted by ERIC, the European Research Initiative on CLL, in HARMONY2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia2023 | Faculty of Medicine in Hradec Králové